PRIMARY MEDIASTINAL B CELL LYMPHOMA
Clinical trials for PRIMARY MEDIASTINAL B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on stubborn lymphoma
Disease control Recruiting nowThis study tests a new approach using a mix of gene-modified immune cells (CAR-T cells) that target multiple proteins found on B cell lymphoma cells. The goal is to see if this combination is safe and can shrink tumors in patients whose cancer has not responded to standard treatm…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for tough lymphomas: balstilimab trial opens
Disease control Recruiting nowThis study tests a drug called balstilimab in 20 adults with certain lymphomas (classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma) that have returned or not responded to standard treatments. Participants receive the drug every 3 weeks to see if it shrinks tumors a…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Immune Oncology Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for lymphoma patients: drug may boost CAR T-Cell success
Disease control Recruiting nowThis phase 2 trial is testing whether the drug loncastuximab tesirine (Lonca) can help patients with large B-cell lymphoma who had only a partial response after CAR T-cell therapy achieve a complete remission. About 30 adults will receive Lonca as a consolidation treatment. The s…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis study tests a personalized cell therapy called Talikabtagene Autoleucel for people with B-cell leukemia or lymphoma that has returned or not responded to standard treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack ca…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: Health Institutes of Turkey • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Engineered immune cells get a metabolic boost to fight blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new version of CAR T-cell therapy that has been modified to improve its energy use, potentially making the cells more effective. It is for adults with certain types of B-cell lymphoma or chronic lymphocytic leukemia that have come back or not r…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug offers hope for lymphoma patients who Can't get transplants
Disease control Recruiting nowThis phase 2 study tests the drug epcoritamab in 30 people with relapsed or refractory large B-cell lymphoma who are not eligible for a stem cell transplant. Epcoritamab is a bispecific antibody that helps the immune system target and kill cancer cells. The main goal is to see ho…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New CAR T-Cell therapy targets tough blood cancers
Disease control Recruiting nowThis study tests a new treatment called SHB-04-CD22, which uses a patient's own immune cells (T-cells) engineered to find and attack cancer cells that have a protein called CD22. It is for children and adults (ages 1-80) with B-cell cancers that have come back or not responded to…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Sheba Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New combo attack on hard-to-treat lymphoma shows promise in early trial
Disease control Recruiting nowThis study tests whether adding two antibody drugs (mosunetuzumab and polatuzumab) after standard CAR-T cell therapy can improve tumor shrinkage in people with aggressive non-Hodgkin lymphoma that has relapsed or not responded to prior treatments. About 22 adults will receive the…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Lazaros Lekakis • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New combo therapy aims to tackle resistant lymphomas
Disease control Recruiting nowThis phase II trial is testing whether adding the JAK inhibitor ruxolitinib to the immunotherapy drug pembrolizumab is safe and effective for people with relapsed or refractory Hodgkin and non-Hodgkin lymphomas. The study will enroll 53 participants with specific lymphoma subtype…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Seda S. Tolu • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Engineered immune cells take on tough lymphoma in new trial
Disease control Recruiting nowThis phase II trial is testing a personalized cell therapy called MB-CART19.1 in 26 adults with CD19-positive non-Hodgkin lymphoma that has relapsed or not responded to prior treatments. The therapy uses a patient's own immune cells, which are modified in the lab to recognize and…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: King Hussein Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Cord blood cells take on lymphoma: new hope for relapsed patients
Disease control Recruiting nowThis early-stage trial tests a new therapy made from cord blood immune cells (CAR NK cells) designed to target and kill B-cell lymphoma cells. It is for patients whose cancer has not responded to or has returned after standard treatments. The study will check safety and how well …
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New gene therapy combo tackles aggressive lymphoma in early trial
Disease control Recruiting nowThis early-stage study is testing a new gene therapy called UB-VV400, alone and with the drug rapamycin, in 70 adults with relapsed or refractory large B-cell lymphoma. The main goals are to find safe doses and check for side effects. Researchers will also look for signs that the…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 17:45 UTC
-
New 'Two-Pronged' CAR-T attack shows promise for tough blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new treatment called OriV508 for people with multiple myeloma or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. OriV508 is a type of immunotherapy that uses a virus to deliver instructions to the body to make…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 26, 2026 14:38 UTC